You are going to love our 2026 Medication PocketCards—designed to help you make quick, informed decisions at the point of care.
GLP-1 & GIP Medications: Now Easier to Compare Than Ever
Our GLP-1 & GIP Meds PocketCard now includes two distinct versions—one for diabetes and one for weight management. This side-by-side approach makes it easier to individualize treatment decisions based on a person’s health profile, age, and comorbidities.
Semaglutide is now available as an oral formulation for weight loss
Exenatide XR (Bydureon®, Bcise®) is discontinued. The only remaining option is generic exenatide.
TZDs: A Farewell and a Comeback
Say goodbye to rosiglitazone and welcome a renewed appreciation for pioglitazone (Actos®).
Pioglitazone decreases insulin resistance – indicated for treatment of hepatic steatosis or post stroke
DPP-4 Inhibitors: Sitagliptin is back
Generic sitagliptin is once again available, so we’ve added it back in the DPP-4 category.
Glucagon PocketCards
This 2-sided card includes all 4 currently available glucagon treatment options on side one. Side two includes hypoglycemia treatment steps and prevention.
The use of DES products does not guarantee the successful passage of the certification exam. CBDCE and ADCES do not endorse any preparatory or review materials for the CDCES or BC-ADM exams, except for those published by CBDCE & ADCES.
We use cookies on this site to enhance your user experience.
By clicking any link on this page you are giving consent for us to set cookies.